 EXTON, Pa., Dec. 15, 2020 GLOBE NEWSWIRE -- Idera Pharmaceuticals, Inc. Nasdaq: IDRA today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement the Purchase Agreement, resulting in aggregate proceeds of up to 20.7 million in common stock and warrant investment by funds affiliated with an institutional investor. Pursuant to the Purchase Agreement, under the second tranche Idera sold 2,747,252 shares of common stock or common stock equivalents, together with accompanying warrants to purchase 1,373,626 shares of common stock, for aggregate gross proceeds of 5.0 million. The placement is exempt from the registration requirements of the Securities Act of 1933, as amended. 